Tourcoing, FRANCE November 19th 2024
The international Macopharma group – GMPi – today announces the acquisition of German company Lmb Technologie – a major player in the blood sector for equipment. Thanks to this strategic alliance, GMPi will enable Macopharma to strengthen its range of blood component processing solutions and consolidate its position in all European, American and Middle Eastern markets.
Two market leaders come together to cover all the needs of players in the blood industry
For over 45 years, Macopharma – whose shareholder is the international Macopharma group GMPi – has been a global player in the blood industry. It offers a range of blood processing solutions combining its expertise in single-use products, filtration, pathogen inactivation, certain equipment and process knowledge. This range helps healthcare professionals by providing safer, higher-quality blood components for the benefit of donors and patients. With 2023 sales of €170 million, Macopharma is continuing to expand, thanks to major innovations resulting from significant investment in research and development, as well as close collaboration with its customers and partners.
Lmb Technologie was founded over 40 years ago in Germany. Dedicated to blood transfusion since 1979, the company is renowned for its equipment and will generate sales of €8m in 2023. Lmb’s portfolio consists of equipment and software (agitators, separators, welders and other accessories): a comprehensive, innovative range and first-rate quality, not to mention expert teams at the service of customers.
This alliance means we can now cover the entire value chain to better meet the needs of blood banks by combining the best of blood kits and filtration, cutting-edge equipment technology, data management software and, above all, recognised service expertise.
A strategic acquisition for Macopharma
This acquisition is part of Macopharma’s 5-year plan to accelerate its solutions offering by strengthening its equipment range, in which Lmb is a major player. The blood industry is evolving through advanced technologies such as automation, data management and artificial intelligence. By joining forces with Lmb, Macopharma aims to gain a stronger position in all European and American markets, as well as in the Middle East. The synergies envisaged are expected to double sales in the equipment business.
Once the final conditions precedent have been met, the Macopharma International group will become Lmb’s sole shareholder, until now held by its founder and his close relations. Macopharma will thus be able to benefit from the exclusivity of Lmb equipment in the geographical areas defined in its 5-year strategy.
For Lmb, joining Macopharma opens greater market opportunities for the 140-strong company. While the two companies were already collaborating on certain contracts and competing in other markets, together they can now offer a wider range and greater capacity. This is critical in the medical devices sector, where business continuity benefits patients. These ambitious projects, which will benefit all our teams, will be set out in greater detail once the acquisition is completed, expected in early 2025.
‘The acquisition of Lmb is a fantastic opportunity for growth and innovation for Macopharma. I am delighted with this alliance because of its commercial and human prospects, as we share the same values and this proximity will be the foundation of our future success.’ states Caroline HERNU, Macopharma CEO.
‘By joining forces with Macopharma, we are taking our business to a more ambitious level. I am confident that our teams will be able to develop their expertise on a much larger scale. This partnership gives us a real competitive edge and opens up some very exciting opportunities for our teams and our customers.’ Klaus Jentsch, Lmb founder
About Macopharma
Founded in 1977 in the North area of France, Macopharma is a major player in blood industry. Its development has always been driven by important innovations resulting from significant investments in research and development and collaborations developed with customers and partners. Macopharma offers a range of blood processing solutions combining expertise on disposables, equipments, softwares and processing guidelines to support healthcare professionals for safer and higher quality blood components for the benefit of donors and patients.
About Lmb Technologie
Lmb was founded over 40 years ago in Germany to become a leading supplier of equipment for the blood industry. Initially, Lmb’s developments focused on blood typing, and it has since evolved to develop a whole portfolio of innovative technologies, from blood collection (mixers, welding machines) to component processing (separators, presses, etc.). The company has been able to meet the needs of blood banks by offering an innovative range, first-rate quality and expert teams at the service of customers. Lmb is now present in Germany, with a test centre, but also in Serbia, with a factory and an R&D centre, and in Turkey for medical activities.